Cybin Inc. filings document Helus Pharma's status as a foreign issuer reporting current events through Form 6-K materials and related exhibits. The filings include company news releases covering the HLP003 and HLP004 clinical programs, regulatory designations, clinical research collaborations, scientific advisory matters, and management changes.
The company's regulatory record also covers capital-structure disclosure, shareholder voting matters, governance matters, clinical or regulatory disclosures, operating and financial results, and risk-oriented cautionary statements associated with its clinical-stage pharmaceutical business.
Cybin Inc. (HELP) filed a Form 6-K as a foreign private issuer for August 2026. The company states that Exhibit 99.1 to this report is incorporated by reference into its existing short-form base shelf registration statement on Form F-10 (File No. 333-292294), including any amendments or supplements. The report is signed on behalf of Cybin Inc. by Chief Financial Officer Greg Cavers on August 18, 2026. No additional financial or transactional details are provided in this filing itself.
Sirenia Capital Management LP and Alex Silverstein report beneficial ownership of Cybin Inc. Common Shares. They collectively report 3,029,500 Common Shares beneficially owned, including 969,500 shares issuable upon exercise of warrants, representing 4.8% of Cybin’s Common Shares outstanding.
Their stake is based on 61,984,078 Common Shares outstanding as of June 29, 2026. All reported shares are held through investment funds managed by Sirenia, with shared voting and dispositive power and no sole voting or dispositive power for either reporting person.
Cybin Inc., doing business as Helus Pharma, reports on progress as a clinical-stage company developing proprietary novel serotonergic agonists (NSAs) for mental health conditions. Lead oral candidate HLP003 for major depressive disorder has FDA Breakthrough Therapy Designation and is in a three-study Phase 3 program (APPROACH, EMBRACE, EXTEND), with APPROACH enrollment completed and topline data targeted for Q4 2026. IM NSA HLP004 has completed a Phase 2 study in generalized anxiety disorder showing clinically meaningful reductions in anxiety and short in-clinic treatment times, with next-study design expected by Q3 2026. Preclinical HLP005 phenethylamine/tryptamine derivatives are advancing toward a potential development candidate in the second half of 2027. Helus Pharma details planned and actual use of approximately $164.3M of October 2025 financing proceeds, heavily focused on HLP003 Phase 3 trials and working capital, and discloses ongoing negative operating cash flow and the need for additional capital. The company highlights an extensive IP estate with over 125 granted patents and hundreds of pending applications worldwide.
Adage Capital Management, L.P. and related parties report beneficial ownership of Cybin Inc. common shares. They report an aggregate of 3,289,250 Common Shares, including 229,250 Common Shares issuable upon exercise of warrants held by Adage Capital Partners, L.P.
This position represents 5.29% of Cybin’s Common Shares, based on 61,984,078 Common Shares outstanding as of June 29, 2026 and assuming exercise of the reported warrants. Voting and dispositive powers over these shares are held on a shared basis among the reporting persons.
Cybin Inc., operating commercially as Helus Pharma, reports that Chief Executive Officer Michael Halstead will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference in Boston, taking place August 11-12, 2026. The session will be webcast live on August 12, 2026, at 12:00 p.m. EDT, with a replay available through the company’s investor relations website.
Helus Pharma is described as a clinical-stage pharmaceutical company developing proprietary novel serotonergic agonists (NSAs) aimed at improving treatments for depression, anxiety, and other mental health conditions. Its lead candidate HLP003 is in Phase 3 development for adjunctive treatment of major depressive disorder and has received U.S. FDA Breakthrough Therapy Designation, while HLP004 is in Phase 2 for generalized anxiety disorder. The company also maintains an extensive NSA research portfolio and operates in Canada, the United States, the United Kingdom, and Ireland, and includes standard forward-looking statement and regulatory disclaimers about its programs.
Cybin Inc., operating as Helus Pharma, has appointed Michael Halstead as Chief Executive Officer, effective immediately. The leadership change comes as HLP003, a proprietary novel serotonergic agonist, progresses through Phase 3 development for adjunctive treatment of major depressive disorder, with enrollment complete in the APPROACH pivotal study and topline data expected in Q4 2026. Enrollment continues in EMBRACE, the second pivotal Phase 3 study, and participants are rolling into EXTEND, a long-term extension study. HLP004 is in Phase 2 for generalized anxiety disorder.
Halstead brings 25 years of industry experience, including serving as President of Intra-Cellular Therapies, where he helped develop and commercialize CAPLYTA and managed the company’s US$14.6 billion sale to Johnson & Johnson. Earlier, he led major transactions at Warner Chilcott, including a US$3 billion acquisition and an US$8.5 billion sale. Helus Pharma highlights an intellectual property portfolio of more than 350 patent applications and more than 100 granted patents worldwide supporting its NSA pipeline. The company cautions that expectations for clinical outcomes, commercialization and growth are forward-looking and subject to risks outlined in its Canadian and U.S. securities filings.
Cybin Inc., operating as Helus Pharma, reports completion of enrollment in its APPROACH Phase 3 pivotal study of HLP003 as an adjunctive treatment for adults with moderate to severe major depressive disorder. The study enrolled 223 participants on stable antidepressants, randomized 1:1 to HLP003 16 mg or placebo, each given as two doses three weeks apart.
The primary endpoint is change from baseline in MADRS at six weeks, with a key secondary endpoint at 12 weeks, and topline data targeted for Q4 2026. HLP003, an investigational deuterated psilocin analogue, has FDA Breakthrough Therapy Designation and in Phase 2 showed a mean ~23-point MADRS reduction 12 months after two 16 mg doses, with 100% response and 71% remission at a MADRS ≤10 benchmark. Enrollment continues in the EMBRACE pivotal study with rollover into the EXTEND long-term extension, and the disclosure is incorporated into the company’s Form F-10 shelf registration, supported by more than 350 patent applications and over 100 granted patents worldwide.
Helus Pharma, the commercial name of Cybin Inc., completed an underwritten offering of 10,309,280 common shares at US$4.85 per share, raising aggregate gross proceeds of US$50 million. Cantor Fitzgerald & Co. and Barclays Capital Inc. acted as joint bookrunning managers, with Bloom Burton Securities Inc. and Lucid Capital Markets as lead managers; the underwriters received a US$3 million cash commission.
The common shares were sold in the United States and certain other jurisdictions outside Canada under a prospectus supplement to Cybin’s Canadian short form base shelf prospectus, also registered with the SEC on Form F-10. The company plans to use net proceeds to advance HLP003 for major depressive disorder, HLP004 for generalized anxiety disorder, HLP005 programs, and for working capital and general corporate needs, with Phase 3 APPROACH data for HLP003 expected in the fourth quarter of 2026.
Cybin Inc., an Ontario, Canada corporation in the health care/biotechnology industry, filed a new notice of an exempt securities offering relying on Rule 506(b) of Regulation D. The issuer was formed over five years ago and lists its principal office in Toronto.
The offering consists of an aggregate of 312,407 restricted share units that vest periodically until July 1, 2029, together with related rights to acquire securities. The date of first sale is stated as July 1, 2026. The total amount sold is reported as $0 USD, and reported finders' fees are $0 USD. For issuer size, Cybin selects the “Decline to Disclose” option for both revenue and aggregate net asset value ranges.
Cybin Inc., an Ontario-based biotechnology corporation, is conducting a private offering of stock options under the Rule 506(b) exemption of Regulation D. The options could generate up to $511,720 in proceeds, representing the maximum potential proceeds from option exercises.
The options are exercisable at $6.61 per share until June 30, 2036, and vest in seven quarterly tranches beginning July 1, 2026. Total amount sold is reported as $0, and the notice lists $0 in finders’ fees.